No-nut diet for Ellagitannins

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Ellagitannins+5 More
No-nut diet - DietarySupplement
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if eating walnuts has any effect on blood lipids and inflammation, as well as gut bacteria.

Eligible Conditions
  • Ellagitannins
  • Walnuts
  • Polyphenols
  • Microbiota
  • Inflammation
  • Cardiovascular Diseases

Treatment Effectiveness

Study Objectives

3 Primary · 5 Secondary · Reporting Duration: Through study completion, an average of 10 weeks

Week 10
Anthropometric measurements
Lipids
Assessing the influence of walnut consumption on blood pressure.
Assessing the influence of walnut consumption on circulating inflammatory markers: PAI-1, VCAM-1 and ICAM-1.
Assessing the influence of walnut consumption on fecal moisture.
Assessing the influence of walnut consumption on fecal pH.
Assessing the influence of walnut consumption on plasma and urine levels of walnut-derived metabolites - urolithins.
Assessing the influence of walnut consumption on stool consistency.
Gastrointestinal tract structure
Food record analysis
Measure of changes in weight

Trial Safety

Trial Design

2 Treatment Groups

No-nut diet
1 of 2
Walnut diet
1 of 2

Active Control

30 Total Participants · 2 Treatment Groups

Primary Treatment: No-nut diet · No Placebo Group · N/A

No-nut diet
DietarySupplement
ActiveComparator Group · 1 Intervention: No-nut diet · Intervention Types: DietarySupplement
Walnut diet
DietarySupplement
ActiveComparator Group · 1 Intervention: Walnuts · Intervention Types: DietarySupplement

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 10 weeks

Who is running the clinical trial?

University of California, DavisLead Sponsor
839 Previous Clinical Trials
5,003,057 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 30th, 2021

Last Reviewed: November 21st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.